ABOUT HEMGENIX

Variety of qualified sufferers: CDEC talked about the uncertainty in the quantity of clients with reasonably significant to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who are classified as owning moderate or reasonable ailment could have a extreme bl